Glaucoma treatments come in two broad options: patient-administered topical systems and invasive clinician-administered systems. Topical systems have the potential to treat glaucoma effectively, but adherence is a problem. Clinician-administered systems can be effective, but tend to be invasive, expensive, and used only after topical systems fail.
“We developed a system that combines the advantages of both topicals and clinician-administered treatments,” said Morgan Fedorchak, PhD, co-founder, Selkie Therapeutics and assistant professor of ophthalmology, University of Pittsburgh School of Medicine. “Our SoliDrop is administered as an eye drop. Once the drop hits the lower fornix, it forms a gel that provides 30 days of continuous release.”
SoliDrop is a thermo-responsive hydrogel carrier with drug-loaded polymer microspheres. At room temperature, the gel is slightly viscous than water. At body temperature, it quickly coalesces into a gel that lodges beneath the lower eyelid.
Preclinical data with brimonidine in rabbits are promising, she added. The gel showed similar IOP-lowering effects as twice-daily brimonidine drops and 100% retention during a 28-day trial.
There was also no change in IOP in the contralateral eye in the SoliDrop group. The eye drop group showed a significant drop in the contralateral eye, a common occurrence.
“This shows a significant decrease in systemic absorption compared to eye drops,” Dr. Fedorchak said. “One reason for that could be that we are administering about 100 times less drug in total using SoliDrop compared to twice daily eye drops.”